TrialThe Lancet. Microbe2025

Effect of the vaginal live biotherapeutic LACTIN-V (Lactobacillus crispatus CTV-05) on vaginal microbiota and genital tract inflammation among women at high risk of HIV acquisition in South Africa: a phase 2, randomised, placebo-controlled trial.

Anke Hemmerling et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.